Correction
9 Nov 2011: Lund O, Nascimento EJM, Maciel M Jr, Nielsen M, Voldby Larsen M, et al. (2011) Correction: Human Leukocyte Antigen (HLA) Class I Restricted Epitope Discovery in Yellow Fewer and Dengue Viruses: Importance of HLA Binding Strength. PLOS ONE 6(11): 10.1371/annotation/254c9f39-1c6b-4f48-a947-b4ed931642e7. https://doi.org/10.1371/annotation/254c9f39-1c6b-4f48-a947-b4ed931642e7 View correction
Figures
Abstract
Epitopes from all available full-length sequences of yellow fever virus (YFV) and dengue fever virus (DENV) restricted by Human Leukocyte Antigen class I (HLA-I) alleles covering 12 HLA-I supertypes were predicted using the NetCTL algorithm. A subset of 179 predicted YFV and 158 predicted DENV epitopes were selected using the EpiSelect algorithm to allow for optimal coverage of viral strains. The selected predicted epitopes were synthesized and approximately 75% were found to bind the predicted restricting HLA molecule with an affinity, KD, stronger than 500 nM. The immunogenicity of 25 HLA-A*02:01, 28 HLA-A*24:02 and 28 HLA-B*07:02 binding peptides was tested in three HLA-transgenic mice models and led to the identification of 17 HLA-A*02:01, 4 HLA-A*2402 and 4 HLA-B*07:02 immunogenic peptides. The immunogenic peptides bound HLA significantly stronger than the non-immunogenic peptides. All except one of the immunogenic peptides had KD below 100 nM and the peptides with KD below 5 nM were more likely to be immunogenic. In addition, all the immunogenic peptides that were identified as having a high functional avidity had KD below 20 nM. A*02:01 transgenic mice were also inoculated twice with the 17DD YFV vaccine strain. Three of the YFV A*02:01 restricted peptides activated T-cells from the infected mice in vitro. All three peptides that elicited responses had an HLA binding affinity of 2 nM or less. The results indicate the importance of the strength of HLA binding in shaping the immune response.
Citation: Lund O, Nascimento EJM, Maciel M Jr, Nielsen M, Voldby Larsen M, Lundegaard C, et al. (2011) Human Leukocyte Antigen (HLA) Class I Restricted Epitope Discovery in Yellow Fewer and Dengue Viruses: Importance of HLA Binding Strength. PLoS ONE 6(10): e26494. https://doi.org/10.1371/journal.pone.0026494
Editor: Man-Seong Park, Hallym University College of Medicine, Republic of Korea
Received: May 31, 2011; Accepted: September 28, 2011; Published: October 19, 2011
Copyright: © 2011 Lund et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIAID contracts HHSN266200400083C, HHSN266200400025C (http://www.niaid.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The Flaviviridae family includes several important human pathogens. These arboviruses include Dengue (DENV), Yellow fever (YFV), West Nile Virus (WNV) and Japanese Encephalites (JEV). All Flavivirus are enveloped, single-stranded RNA (+) viruses coding for a polyprotein precursor of approximately 3,400 amino acids, which is cleaved into three structural (capsid, C; precursor membrane and membrane, prM/M; envelope, E) and seven nonstructural proteins (NS1, 2a, 2b, 3, 4a, 4b and 5) [1], [2].
Flavivirus infection, in general, elicits long-lasting immunity. Accumulated evidence indicates that neutralizing antibody responses are associated with protection, and increasing evidence suggests that T-cell CD4+ and CD8+ responses also play critical roles reducing morbidity and mortality. The T-cells can mediate protection against Flavivirus by CD4+ helper stimulation of B-cells and by direct killing of infected cells by CD8+ cytotoxic leukocytes (CTL). CD4+ and CD8+ cells have been shown to be essential for protection against WNV, and CD8+ T-cells have been shown to provide protective immunity against DENV [3], [4], [5], [6], [7], [8] and YFV infections [9], [10].
Flavivirus, as other RNA viruses, has a relatively high mutation rate and uses this mechanism to evade the host immune responses. In particular, DENV has four different serotypes and immunological memory responses, either B- or T-cell, have been shown to be involved in DENV pathogeneses.
Only few vaccines are currently available against Flavivirus, among these are the attenuated virus vaccines for YFV and the inactive viral protein formulation for JEV. No DENV vaccine is available for clinical use [7]. The virus-based YFV vaccines are associated with several adverse side effects and frequent fatal reactions [11], [12], while the JEV vaccine is relatively weak and prone to induce allergic reactions [13], [14], [15], [16]. Taken together, this indicates the need for development of novel and better Flavivirus vaccines.
Recent advances on epitope discovery and antigen delivery technologies have enabled the development of broadly effective epitope based vaccine formulations. Epitope vaccines are potentially safer since they focus the immune response towards defined epitopes associated with protection, thereby minimizing cross-reactions with the potentially pathogenic epitopes [17], [18], [19], [20], [21], [22]. The objective of this study was to identify HLA-I restricted epitopes covering 12 HLA-I supertypes (A1, A2, A3, A24, A26, B7, B8, B27, B 39, B44, B58 and B62) within conserved regions across all four DENV serotypes and YFV strains. The bioinformatics approaches for selection of the epitopes that provide optimal strain coverage were described previously [23] and the HLA-I binding affinity of the selected peptides were determined using conventional biochemical binding assays [24], [25]. In addition, the immunogenicity of the A2, A24 and B7 HLA-I supertype epitopes were determined in HLA-A*02:01, HLA-A*24:01 and HLA-B*07:02 transgenic mice models [1], [2].
Materials and Methods
Bioinformatics
The HLA-I epitope predictions were performed on the basis of a dataset consisting of all strains of YFV and DENV that were fully sequenced in May 2006 and available in the GenBank or RefSeq databases. Epitopes restricted to any of the A1, A2, A3, A24, A26, B7, B8, B27, B 39, B44, B58 and B62 supertype representatives were predicted using an inhouse version 1.0 of the NetCTL method including prediction for the A26 and B39 supertypes [26]. In the NetCTL method, each possible 9mer peptide in a protein is assigned a score based on a combination of proteasomal cleavage, TAP transport efficiency, and HLA-I binding affinity, with the highest weight assigned to HLA-I affinity.
For YFV, we selected the 16 top-scoring 9mer peptides per supertype for each of the 12 fully sequenced YFV genomes: NC_002031 AY640589 AY603338 AY572535 U54798 AF094612 U21055 U21056 X03700 U17067 U17066 X15062. Next, the EpiSelect algorithm was used for selecting a number of predicted epitopes, which together constitute a broad coverage of all strains. The EpiSelect algorithm has been described in detail previously [23]. Briefly, it aims at selecting a number of epitopes in a way so that the number of selected epitopes in the viral strain with the fewest selected epitopes is as high as possible. Application of the EpiSelect algorithm identified 179 unique candidate epitopes, which are present on average in at least 11 out of the 12 genomes.
For DENV, the 15 top-scoring 9mer peptides per supertype were selected for each of the 36 fully sequenced DENV genomes DENV-1: NC_001477 AY762084 AB189121 AY277664 AF311958 AF226685 AY145121 AB074761 U88537, DENV-2: NC_001474 AY702038 AY702035 AY858036 AY744147 AB122020 AB189124 AF169688 AF169685 AF169682 AF169679 AF276619 AF119661 AF022439 AF022436 M29095, DENV-3: AY923865 AY858039 AY648961 AB189127 AY662691 AY099337 AF317645 AY947539, DENV-4: AY762085 AF326573 AF375822. Application of the EpiSelect algorithm identified 158 unique candidate epitopes, which are present on average in at least 35 of the 36 genomes.
Peptides
The 9mer peptides were synthesized by standard 9-fluorenylmethyloxycarbonyl (FMOC) chemistry, and purified by reversed-phase high-performance liquid chromatography (at least 80%, usually >95% purity) and validated by mass spectrometry (Shafer-N, Copenhagen, Denmark). Peptides were distributed at 500 µg/vial and stored lyophilized at −20°C until use. Peptides were dissolved at 2 mg/mL just before use with 10% (v/v) DMSO (Sigma).
Biochemical peptide-HLA-I binding assay
The biochemical assay for peptide–HLA-I binding was performed as previously described [24], [25]. Briefly, denatured and purified recombinant HLA heavy chains were diluted into a renaturation buffer containing HLA heavy chain, β2-microglobulin and graded concentrations of the test peptide, and incubated at 18°C for 48 h allowing equilibrium to be reached. We have previously demonstrated that denatured HLA molecules can de novo fold efficiently, however, only in the presence of appropriate peptides [27]. The concentration of peptide–HLA complexes generated was measured in a quantitative enzyme-linked immunosorbent assay and plotted against the concentration of peptide offered [24]. Because the effective concentration of HLA (3–5 nM) used in these assays is below the equilibrium dissociation constant (KD) of most high-affinity peptide–HLA interactions, the peptide concentration leading to half-saturation of the HLA is a reasonable approximation of the affinity of the interaction. An initial screening procedure was employed whereby a single high concentration (20,000 nM) of peptide was tested. If no complex formation was found, the peptide was assigned as a non-binder to the HLA molecule in question, conversely, if complex formation was found in the initial screening, a full titration of the peptide was performed to determine the affinity of binding to HLA.
Animals and immunization protocols
Transgenic mice expressing either HLA-A*02:01 [20], HLA-A *24:02 (Lemonier et al., unpublished) or HLA-B*07:02 [21] were used in the immunization protocols. They were bred and maintained in the Johns Hopkins University School of Medicine Animal Facility. Specific pathogen-free colonies were maintained in a helicobacter-negative mice facility. HLA expression of the experimental transgenic mice was evaluated by flow cytometry using anti HLA-A2 PE (BD Biosciences Pharmigen), anti HLA-A24 PE (MBL) or anti HLA-B7 FITC (Abcam). Mice were immunized subcutaneously (tail base) twice, two to three weeks apart, with 100 µL of pool of peptides (1 µg per peptide) dissolved in PBS and emulsified in TiterMax (CytRx Corporation). Control animals were immunized with DMSO dissolved in PBS and emulsified in TiterMax. Different immunization pools were used according to the transgenic mice and the organism by which the epitopes were predicted from (Table S1). For each experiment, nine mice where immunized with the peptide pools, while three naïve mice were used as controls. Immunization with YF vaccine was also performed subcutaneously with three doses of 104 plaque forming units (PFU) of the attenuated virus, at two weeks interval.
The presence of the HLA transgene in each mouse was confirmed by PCR during breading stages. However, the expression of the HLA gene in this strain of mice is unstable and therefore we screened all the mice with immune staining and flow cytometric analyses and selected for the immunization experiments only the mice that presented high levels of HLA protein expression.
Ethics Statement
All experiments were approved by the Johns Hopkins Animal Care and Use Committee under protocol number MOO7M78.
ELISPOT assays for enumeration of IFN-γ spot-forming cells (SFC)
Two weeks after the last immunization, the mice were sacrificed and their spleens removed. Splenocytes were isolated and red cells were lysed with ACK buffer (Pierce). CD4+ cells were depleted using anti mouse CD4 microbeads and LD columns according to the manufacturer manual (Myltenyl). The CD4-depleted splenocytes were dissolved in complete RPMI 1640 medium (supplemented with 10% v/v fetal bovine serum (FBS), 100 U/mL penicillin/streptomycin, 2 mM Lglutamine, 50 µM 2-mercaptoethanol and 1 M HEPES buffer). IFN-γ ELISPOT assays were performed by using an ELISPOT set according to the manufacturer's protocol (BD Biosciences Pharmingen). Initially, the ELISPOT plates were coated with anti-IFN-γ at 5 µg/mL and incubated at 4°C overnight. The plates were blocked with RPMI 1640 containing 10% FBS for 2 h at room temperature. Then, each peptide was added into ELISPOT plate at 10 µg/mL, 1 µg/mL and 0.1 µg/mL in complete RPMI. After that, CD4-depleted splenocytes from either immunized or control mice were plated at 0.5 to 1×106 cells per well and incubated for 16–18 hs at 37°C, 5% CO2. Media only and concanavalin A (Sigma) were used as negative (background) and positive control respectively. The plates were washed and incubated with biotinylated anti-IFN-γ for 2 h at room temperature, followed by HRP-conjugated avidin for 1 h at room temperature. Reactions were developed with AEC substrate (BD Biosciences). IFN-γ spot forming cells (SFC) were enumerated with the Immunospot Series 3B Analyzer ELISPOT reader, using the Immunospot software version 3.0 (Cellular Technologies Ltd). The data shows the number of SFC/106 cells. The peptides were considered T-cell epitopes if (i) they elicited IFN-γ SFC minus background greater than 10; and (ii) IFN-γ SFC minus 2 standard deviations (SD) must be greater than the background (negative control) plus 2 SD.
YF vaccine
The human YF vaccine, composed of attenuated 17DD YF virus, was a generous gift from Dr. Ricardo Galler (Oswaldo Cruz Foundation, Rio de Janeiro, Brazil). The vaccine was reconstituted with chilled PBS, kept in an ice bath, and used for immunization of mice within 4 h of reconstitution.
Statistics
Wilcoxon rank sum tests and Fishers exact tests were performed using the commands wilcox.test(), and fisher.test() implemented in R stats package (http://sekhon.berkeley.edu/stats/html/00Index.html).
Results
Flavivirus HLA-I binding peptides
Yellow fever epitopes: 179 YFV peptides covering 12 HLA-I supertypes (A1, A2, A3, A24, A26, B7, B8, B27, B 39, B44, B58 and B62) were selected using NetCTL and EpiSelect. 171 of these could be synthesized and were tested for binding to their respective HLA-I. 121 (71%) of these were found to bind to their predicted restricting HLA-I element with a KD stronger than 500 nM. For a peptide to be immunogenic, it is generally considered a prerequisite that it binds its HLA-I molecule with a KD below 500 nM, since it has been shown that more than 90% of the peptides recognized by CD8+ T-cells bind with a KD below this threshold [28].
Dengue epitopes.
158 DENV peptides, which together represents all four serotypes and cover the 12 HLA-I supertypes were selected using same procedure as for the YFV epitopes. 147 were synthesized and 116 (79%) were found to bind with a KD below 500 nM. A schematic diagram of the selection scheme is shown in figure 1.
In addition to the 237 good binders, 5 weak binders and one non-binder was also tested in this study for comparison, but these are not included in the figure.
All the peptide sequences along with their binding affinities for the HLA-I alleles were deposited at the Immune Epitope Database (IEDB) (http://www.immuneepitope.org/) and are shown in Table S2.
Immunogenicity of the A*02:01, A*24:03 and B*07:02 binding peptides
The immunogenicity of peptides binding to representatives of the A2, A24 or B7 HLA-I supertypes with high affinity was tested in transgenic mice models (Table S1). The animals were immunized with these peptides and the T-cell immune responses tested individually by ELISPOT assays as described in materials and methods. The immunogenicity of 82 peptides from both YFV and DENV comprising 25 A*02:01, 28 A*24:03, 28 B*07:02 binders and one non-binding peptide were tested.
Among the A*02:01 binding peptides, 17/25 (68%) were able to elicit a significant immune response under this immunization protocol in at least two individual animals (Table 1). No significant responses were observed in negative control mice or against the HLA non-binding peptide (LVAGGLLTV). The binding affinity was found to be significantly correlated with eliciting responses (p = 0.01, Wilcoxon test). When considering the peptides with a measured affinity below 5 nM to HLA-A*02:01, 12/14 (86%) of the peptides elicited a response which was significantly more than the 5/12 (42%) of the poorer binders (p<0.05, Fishers exact test).
Among the A*24:03 binding peptides, 4/28 (14%) were able to elicit a significant immune response in at least two individual animals (Table 2). We were not able to use exactly the same A24 allele for the binding assays and the animal studies, but the specificity of the two molecules is predicted to be very similar (http://www.cbs.dtu.dk/biotools/MHCMotifViewer/). When immunizing using the peptides with an affinity below 5 nM to HLA-A*24:03, 1/3 (33%) elicited a significant response, whereas a response was observed for only 3/25 (12%) of the peptides binding with an affinity above 5 nM. Here, we hence also find that the likelihood of inducing a CTL response was highest for the strongest binding peptides. The difference between the two groups was not, however, found to be statistically significant (p = 0.27, Fishers exact test).
Among the B*07:02 peptides, 4/28 (14%) were able to elicit detectable responses in the B*07:02 mice (Table 3). None of the five peptides with binding affinities below 5 nM induced an immune response. Three of the fourteen peptides (21%) with affinities between 5 and 100 nM induced immune responses. The correlation between affinity and immune response was neither statistically significant when using Wilcoxons test, nor Fishers exact test with at affinity threshold of 5 nM. One of the nine peptides with a binding affinity above 100 nM elicited a response, however, it appears to be an outlier, since the peptide's measured affinity for the B*07:02 molecule is 6,769 nM. The peptide was originally predicted to bind to B*07:02 with an affinity of 328 nM. Using the latest version 2.4 of NetMHCpan (/www.cbs.dtu.dk/services/NetMHCpan/), the peptide is predicted to bind to B*07:02 with an affinity of 3,529 nM. Given this very low binding affinity to B*07:02 it seems likely that this peptide is restricted by another peptide presenting molecule. Discarding this outlier, we find for B*07:02 that 3 out of the 19 peptides with an affinity stronger than 100 nM elicit a response where this is the case for none of the 9 peptides with an affinity weaker than 100 nM. The fraction of responding peptides as a function of the affinity is summarized in table 4.
It is known that antigen processing plays an important role in shaping the immune dominance. To investigate the effect of processing on the YFV epitopes, the A*02:01 mice were inoculated twice with a dose of 104 PFU of 17DD YFV strain, which is attenuated, but able to replicate in mice. The spleens of the inoculated mice were harvested and the significant T-cell responses evaluated by ELISPOT using the selected A*02:01 peptides (Table 5). Of the three YFV A*02:01 peptides that activated the T-cells from the infected mice in vitro, two had previously been shown to be immunogenic and the third, which did not show consistent results with the peptide immunization, now appeared in three separate assays. All three peptides that elicited responses had an HLA-I binding affinity of 2 nM or less. The peptides eliciting responses had stronger HLA binding affinities (average 1.3 nM) than those that did not give a response (average 156 nM). This difference was, however, only borderline significant (p = 0.068; Wilcoxon rank sum test). The peptides that elicited a response when using the 17DD YFV strain to vaccinate also had stronger HLA binding affinities than those that gave response when using A*02:01 peptides from YFV to vaccinate (average 47 nM) but this difference was not significant (p = 0.23; Wilcoxon rank sum test). A similar experiment was also performed in the B*07:02 mice, but no T-cell responses were detected in the B*07:02 mice inoculated with the 17DD virus. A similar experiment was not performed in A*24:02 mice since, unfortunately, these mice were no longer available in our laboratory.
When the peptides giving significant responses were tested in vitro at different concentrations, five peptides (two DENV and three YFV) that induced responses in A*02:01 mice showed high functional avidity achieving approximately half the maximal of the T-cell responses at peptide concentrations as low as 0.1 µg/mL (Figure 2). The A*02:01 response was specific, since no peptide from the B*07:02 set (used as negative controls) induced any response in A*02:01 mice (data not shown). Three of the A*24:03 immunogenic peptides elicited high affinity responses (Figure 3). Note that all the peptides that were found to be immunogenic in transgenic B*07:02 mice only activated CTLs at the highest concentration used, 10 µg/ml. Since we have only made graphs of peptides that elicited a response at 0.1 µg/ml, they were not included in any figure.
Peptides positive at concentration 0.1 µg/mL and greater are shown. Results are depicted as percentage of spot-forming cells/million cells of each peptide at 10 µg/mL.
Peptides positive at concentration 0.1 µg/mL and greater are shown. Results are depicted as percentage of spot-forming cells/million cells of each peptide at 10 µg/mL.
Discussion
In this study, we identified 179 yellow fever and 158 dengue peptides as putative HLA-I binders using the NetCTL algorithm. Approximately 75% of these peptides bound to at least one of the 12 representatives for the HLA-I supertypes with a KD below 500 nM. The immunogenicity of 25 HLA-A*02:01, 28 HLA-A*24:03 and 28 HLA-B*07:02 binders was tested in three HLA-transgenic mice models and led to the identification of 17 HLA-A*02:01, 4 HLA-A*24:03 and 4 HLA-B*07:02 immunogenic peptides. All except two of the immunogenic peptides had KD below 100 nM, and the peptides with IC50 below 5 nM were more likely to be immunogenic. In addition, all the immunogenic peptides that were identified as having a high functional avidity (induce more then 50% of maximum response with 0.1 µg/ml of peptide) had KD below 20 nM.
Considering all three HLA-I types and all 82 tested peptides together, 22 peptides had KD below 5 nM and 13 (59%) of those were immunogenic. Considering the 64 peptides that had affinities to their respective HLA below 100 nM, 23 (36%) induced immune responses, whereas only two of seventeen (12%) of the peptides with KD above 100 nM induced immune responses. For each of the three HLA-I molecules included in this study, we observe an inverse correlation between the likelihood of a peptide binder of inducing a CD8 response and the binding affinity. However, this correlation between the peptide-HLA binding affinity and immunogenicity in the respective transgenic mice model appears to differ according to the HLA type. Among the three HLA-I types evaluated, A*02:01 showed the highest correlation between HLA binding affinity and immunogenicity, since 86% of the peptides with KD below 5 nM induced responses. The reason we did not see a significant correlation for A*24:03 and B*07:02 may be that we found relatively fewer responding peptides for these alleles as compared to A*02:01.
These differences in correlation between HLA binding affinity and immunogenicity may be due to differences in the levels of expression of the HLA molecule in the transgenic mice model or other artifacts of these artificial animal models. However, it could also be due to intrinsic differences on the forces of interactions of specific HLA alleles with the CD8 molecules or with the T-cell receptor that would lead to different requirements of MHC-peptide affinities for optimum T-cell activation. If this is true, it is possible that different HLA alleles preferentially induce responses to peptides with distinct ranges of MHC-peptide binding affinities. This latter speculation is in accordance with earlier observations by Rao et al. [29].
In conclusion, we have described the predicted top binding peptides, all highly conserved in YFV and DENV, for the 12 HLA-I supertypes (see table S2). The potential immunogenicity of these peptides was evaluated in mice models transgenic for three different HLA types and more than half of the peptides with KD below 5 nM for the HLA-1 molecule in question were indeed immunogenic.
Supporting Information
Table S1.
Peptides analyzed and immunization pools.
https://doi.org/10.1371/journal.pone.0026494.s001
(DOC)
Table S2.
Binding affinities for YFV and DFV peptides.
https://doi.org/10.1371/journal.pone.0026494.s002
(DOC)
Author Contributions
Conceived and designed the experiments: OL MVL ETAM TJA SB. Performed the experiments: EJMN MM MN CL MH KL JS. Analyzed the data: OL JS EJMN. Contributed reagents/materials/analysis tools: MN CL. Wrote the paper: OL MN ETAM.
References
- 1. Khan AM, Miotto O, Nascimento EJ, Srinivasan KN, Heiny AT, et al. (2008) Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis 2: e272.
- 2. Khan AM, Miotto O, Heiny AT, Salmon J, Srinivasan KN, et al. (2006) A systematic bioinformatics approach for selection of epitope-based vaccine targets. Cell Immunol 244: 141–147.
- 3. Loke H, Bethell DB, Phuong CX, Dung M, Schneider J, et al. (2001) Strong HLA class I–restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis 184: 1369–1373.
- 4. Lu Y, Raviprakash K, Leao IC, Chikhlikar PR, Ewing D, et al. (2003) Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. Vaccine 21: 2178–2189.
- 5. Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, et al. (2001) Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology 290: 74–82.
- 6. Screaton G, Mongkolsapaya J (2006) T cell responses and dengue haemorrhagic fever. Novartis Found Symp 277: 164–171; discussion 171–166, 251–163.
- 7. Thomas SJ, Hombach J, Barrett A (2009) Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 27: 355–368.
- 8. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, et al. (2009) A protective role for dengue virus-specific CD8+ T cells. J Immunol 182: 4865–4873.
- 9. Co MD, Terajima M, Cruz J, Ennis FA, Rothman AL (2002) Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293: 151–163.
- 10. van der Most RG, Harrington LE, Giuggio V, Mahar PL, Ahmed R (2002) Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 296: 117–124.
- 11. Domingo C, Niedrig M (2009) Safety of 17D derived yellow fever vaccines. Expert Opin Drug Saf 8: 211–221.
- 12. Roukens AH, Visser LG (2008) Yellow fever vaccine: past, present and future. Expert Opin Biol Ther 8: 1787–1795.
- 13. Duggan ST, Plosker GL (2009) Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]. Drugs 69: 115–122.
- 14. Ferguson M, Kurane I, Wimalaratne O, Shin J, Wood D (2007) WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1–2 June 2006. Vaccine 25: 5233–5243.
- 15. Pengsaa K, Limkittikul K, Sabchareon A, Ariyasriwatana C, Chanthavanich P, et al. (2009) A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old thai children, concomitantly with Japanese encephalitis vaccine. Pediatr Infect Dis J 28: 335–337.
- 16. Tauber E, Dewasthaly S (2008) Japanese encephalitis vaccines–needs, flaws and achievements. Biol Chem 389: 547–550.
- 17. Braga-Neto UM, Marques ET Jr (2006) From functional genomics to functional immunomics: new challenges, old problems, big rewards. PLoS Comput Biol 2: e81.
- 18. Brusic V, August JT, Petrovsky N (2005) Information technologies for vaccine research. Expert Rev Vaccines 4: 407–417.
- 19. De Groot AS (2006) Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 11: 203–209.
- 20. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, et al. (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185: 2043–2051.
- 21. Rohrlich PS, Cardinaud S, Firat H, Lamari M, Briand P, et al. (2003) HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int Immunol 15: 765–772.
- 22. Sette A, Fleri W, Peters B, Sathiamurthy M, Bui HH, et al. (2005) A roadmap for the immunomics of category A–C pathogens. Immunity 22: 155–161.
- 23. Perez CL, Larsen MV, Gustafsson R, Norstrom MM, Atlas A, et al. (2008) Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. J Immunol 180: 5092–5100.
- 24. Sylvester-Hvid C, Kristensen N, Blicher T, Ferre H, Lauemoller SL, et al. (2002) Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. Tissue Antigens 59: 251–258.
- 25. Sylvester-Hvid C, Nielsen M, Lamberth K, Roder G, Justesen S, et al. (2004) SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation. Tissue Antigens 63: 395–400.
- 26. Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, et al. (2005) An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 35: 2295–2303.
- 27. Ostergaard Pedersen L, Nissen MH, Hansen NJ, Nielsen LL, Lauenmoller SL, et al. (2001) Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds. Eur J Immunol 31: 2986–2996.
- 28. Yewdell JW, Bennink JR (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17: 51–88.
- 29. Rao X, Costa AI, van Baarle D, Kesmir C (2009) A comparative study of HLA binding affinity and ligand diversity: implications for generating immunodominant CD8+ T cell responses. J Immunol 182: 1526–1532.